This information is intended for use by US healthcare providers only. Visit the RELIEF Clinical Trial >>
Learn More About a Phase III Study for Patients with Polycythemia Vera
A phase III study investigating ruxolitinib—an oral JAK1 and JAK2 inhibitor
On this Web site, you will find information on the RESPONSE clinical trial evaluating the investigational agent ruxolitinib for the treatment of polycythemia vera. Additional useful resources include trial recruitment information and brief overviews of selected topics such as polycythemia vera, the Janus kinase (JAK) pathway, and preliminary clinical results.